AGEN7:30 AMAgenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026Presentation / Abstractagenusbio.com
AGEN7:00 AMAgenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026Presentation / Abstract • Phase 1agenusbio.com
AGEN5:00 PMAgenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026Presentation / Abstract • Phase 2agenusbio.com
AGEN5:00 PMAgenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRCagenusbio.com
AGEN4:11 PMAgenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Canceragenusbio.com
AGEN8:45 AMAgenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Developmentagenusbio.com
AGEN10:00 AMAgenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026Presentation / Abstract • Phase 2agenusbio.com
AGEN8:00 AMAgenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programsagenusbio.com
AGEN4:43 PMAgenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal CancerTrial Results • Phase 2agenusbio.com